Immutep Ltd Stock Australian S.E.
Stocks
AU000000PRR9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 67.79M 47.66M 41.35M 38.72M 35.39M 66.79M 4.53B 453M 178M 2.27B 179M 175M 7.55B | P/E 2026 * |
-1.19x | P/E 2027 * | -1.69x |
|---|---|---|---|---|---|
| Enterprise Value | 2.79M 1.96M 1.7M 1.6M 1.46M 2.75M 187M 18.67M 7.33M 93.63M 7.37M 7.21M 311M | EV / Sales 2026 * |
0.16x | EV / Sales 2027 * | -2.97x |
| Free-Float |
96.98% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +4.55% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 2014-07-08 |
David Fang
DFI | Director of Finance/CFO | - | 2018-02-28 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 2014-07-08 |
Russell Howard
CHM | Chairman | 76 | 2017-11-16 |
Pete Meyers
BRD | Director/Board Member | 57 | 2014-02-11 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.55% | +4.17% | - | - | 48.86M | |
| +0.93% | -1.43% | +1.61% | +14.93% | 48.57B | |
| +0.26% | +9.34% | +415.26% | +533.80% | 41.95B | |
| -1.53% | -6.11% | +26.37% | +7.15% | 38.85B | |
| +0.69% | +0.79% | +7.35% | +63.05% | 37.24B | |
| +2.47% | +8.33% | +15.16% | +48.37% | 30.67B | |
| -0.47% | +0.01% | +34.08% | +126.09% | 16.41B | |
| +2.31% | -0.87% | - | - | 16.1B | |
| +0.29% | +1.81% | +4.92% | +18.60% | 13.97B | |
| -1.43% | -9.55% | -2.90% | -36.38% | 12.62B | |
| Average | +0.80% | -0.30% | +62.73% | +96.95% | 28.48B | |
| Weighted average by Cap. | +0.44% | +0.39% | +82.62% | +121.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.23M 12.12M 10.51M 9.84M 9M 16.98M 1.15B 115M 45.2M 578M 45.48M 44.49M 1.92B | 3.16M 2.22M 1.93M 1.8M 1.65M 3.11M 211M 21.1M 8.28M 106M 8.33M 8.15M 352M |
| Net income | -58.54M -41.16M -35.71M -33.43M -30.56M -57.67M -3.91B -391M -154M -1.96B -154M -151M -6.52B | -47.05M -33.08M -28.7M -26.87M -24.56M -46.35M -3.15B -314M -123M -1.58B -124M -121M -5.24B |
| Net Debt | -65M -45.7M -39.65M -37.12M -33.94M -64.04M -4.35B -434M -170M -2.18B -172M -168M -7.24B | -77.18M -54.26M -47.08M -44.08M -40.29M -76.04M -5.16B -516M -202M -2.59B -204M -199M -8.6B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
